Challenges of PK/PD measurements in modern drug development.
Workman
P
P
Cancer Research UK Centre for Cancer Therapeutics, Institute of Cancer Research, Sutton, Surrey SN2 5NG, UK. paulw@icr.ac.uk
D000970:Antineoplastic Agents / Q000493:pharmacokinetics* / Q000494:pharmacology*; D016227:Benzoquinones; D015687:Cell Hypoxia / Q000502:physiology; D015195:Drug Design; D018841:HSP90 Heat-Shock Proteins / Q000502:physiology; D006801:Humans; D047029:Lactams, Macrocyclic; D018832:Molecular Chaperones / Q000037:antagonists & inhibitors; D009593:Nitroimidazoles; D017828:Rifabutin / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology
D000970:Antineoplastic Agents; D016227:Benzoquinones; D018841:HSP90 Heat-Shock Proteins; D047029:Lactams, Macrocyclic; D018832:Molecular Chaperones; D009593:Nitroimidazoles; D017828:Rifabutin; C112765:tanespimycin; C095171:SR 4554